Treatment should only be continued if there has been a beneficial metabolic response, defined as a reduction in HbA1c of at least 11 mmol/mol (1.0%) and weight loss of at least 3% of initial body weight
The plasticity of pancreatic cells, enabling them to acquire -cell identity, is considered a potential therapeutic strategy for diabetes, either through activation of endogenous regenerative mechanisms or through the generation of functionally mature -cells under controlled in vitro conditions, as we have detailed in our previous review (Saleh et al., 2021
Weight reduction Weight loss was similar between dulaglutide and exenatide twice daily but was greater with liraglutide compared to dulaglutide ( Figure 4 )
With obesity comes risks such as type 2 diabetes, heart disease, stroke, cancer, sleep apnea, etc
doi:10.1503/jpn.100057